Skip to main content
logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
15.53
+0.18 (1.17%)
At close: Aug 21, 2026, 4:00 PM EDT
15.47
-0.06 (-0.42%)
After-hours: Aug 21, 2026, 7:30 PM EDT

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
3816541874898651,861
Market Cap Growth
86.00%249.70%-61.73%-43.52%-53.52%-
Enterprise Value
199387-215-45182992
Last Close Price
15.5330.7812.8038.8069.40154.80

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
14094.9918163.583065.303758.6610.22174.77
PB Ratio
1.552.640.490.751.042.00
P/TBV Ratio
1.632.640.490.751.042.00

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
7376.4810759.39--2.1593.15

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.200.210.150.100.080.07
Net Debt / Equity Ratio
-0.78-0.79-0.85-0.76-0.77-0.89
Net Debt / EBITDA Ratio
1.001.051.632.223.804.15
Net Debt / FCF Ratio
1.351.301.993.003.324.33
Asset Turnover
00000.080.01
Quick Ratio
5.125.006.8915.8217.2913.15
Current Ratio
5.365.287.0616.0717.5913.40
Return on Equity (ROE)
-93.28%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-34.18%-29.83%-22.05%-18.18%-11.32%-13.11%
Return on Capital Employed (ROCE)
-70.20%-68.20%-50.10%-34.30%-20.80%-19.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-65.29%-41.97%-183.44%-48.02%-21.17%-13.44%
FCF Yield
-35.20%-23.06%-87.10%-34.05%-22.40%-10.30%
Buyback Yield / Dilution
-49.16%-30.74%-4.18%-1.58%-81.79%-925.18%
SEC Filings: 10-K · 10-Q